BASEL, Switzerland, Sept. 02, 2022 (GLOBE NEWSWIRE) — Myovant Sciences MYOVa biopharmaceutical company dedicated to serving women and men through intent-driven science, drug empowerment, and transformative advocacy Business Officer, will participate in the following upcoming investor conferences:
- Citi’s 17th Annual BioPharma Conference on Thursday, September 8, 2022. Management will participate in one-on-one meetings with investors.
- Baird 2022 Global Health Conference On Tuesday, September 13, 2022 at 12:15 p.m. Eastern Time, Mr. Marek and Mr. Mehra will participate in a fireside chat. Management will also participate in one-on-one meetings with investors on September 13th.
Investors and the general public are invited to listen to the Baird fireside chat, which will be accessible on the Events page at Investors & Media section of the Myovant website at www.myovant.com.
ABOUT MYOVANT SCIENCES
Myovant Sciences strives to redefine care for women and men through purposeful science, empowering medicines and transformative advocacy. Founded in 2016, Myovant has completed five successful Phase 3 clinical trials in the areas of oncology and women’s health, resulting in three regulatory approvals from the U.S. Food and Drug Administration (FDA) for men with advanced prostate cancer, women with heavy menstrual bleeding in Associated with uterine fibroids, or premenopausal women with moderate to severe pain associated with endometriosis. Myovant has also received regulatory approvals from the European Commission (EC) and the UK Medicines and Healthcare Products Regulatory Agency (MHRA) for women with symptomatic uterine fibroids and for men with advanced hormone-sensitive prostate cancer. Myovant has reviewed a new drug supplemental application with the FDA to provide updates for the United States…
